The Food and Drug Administration’s vaccine chief, Dr. Vinay Prasad, will depart the agency next month, an FDA spokesperson ...

The Food and Drug Administration’s controversial vaccine chief, Dr. Vinay Prasad, is once again leaving the agency.

Vinay Prasad, the top regulator overseeing vaccines and complex treatments for difficult diseases, had previously lost his job in July before getting it back less than two weeks later.

Dr. Vinay Prasad will depart in April, after a year leading the division that approves vaccines and biotech drugs.

Vinay Prasad, director of the Center for Biologics Evaluation and Research, will leave the FDA at the end of April, an agency ...

The ​controversial head of the U.S. Food and Drug Administration's vaccines and biologics unit, Dr. Vinay Prasad, ‌will leave the agency at the end of April.

Lots of people are talking about peptides. But what are they? Here’s a quick primer on the health trend and what we know about peptides’ safety.

The End the Vaccine Carveout Act would expose vaccine makers to lawsuits that once drove companies out of the industry.

But just a week lat­er, on Feb. 18, the FDA back­tracked on its decision, saying that it will indeed review the vaccine, potentially in time for its approval for the ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...

Moderna stock is rising after the company agreed to pay up to $2.25 billion to settle a patent dispute over technology used ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine ...